Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
A recent analysis found that health care providers missed opportunities to test 90% of such patients.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Federal judge rules in favor of nonprofit seeking to open the country’s first overdose prevention facility.
Researchers point to heroin use as a major driver of new hepatitis C and HIV cases among people who inject drugs.
Restricting the testing program to only people who inject drugs did not improve its cost effectiveness.
Opioid use disorder is fueling a rise in youth hepatitis C cases and a stabilization of a long decline in HIV among people who use drugs.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
U.S. health care systems are seeking better solutions to the critical problem of drug diversion.
This includes people who use drugs, those with psychiatric disorders and those with a history of alcohol use.
A pooled analysis of numerous clinical trials and real-world studies reached this conclusion.
New cases of all three viruses have declined in the city over the past decade.
Consistent use of medication-assisted treatment for opioid use disorder can apparently reduce this risk.
An analysis of newly diagnosed youths in California found they had limited access to opioid-related harm reduction services.
The drug can quickly reverse opioid-driven overdoses.
An analysis of hepatitis B testing among women of childbearing age found a declining national rate but increases in several states.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.